Abstract
Concentrations of misonidazole and its O-demethylated metabolite Ro 05-9963 in the plasma and saliva of 10 patients with malignant disease have been determined. A good linear correlation was established between plasma and saliva misonidazole concentration, and salivary sampling was found to be suitable for the estimation of a number of pharmacokinetic parameters. Data are also presented for serial tumour cencentrations of misonidazole and Ro 05-9963 in 3 of the 10 patients. Monitoring of salivary misonidazole concentration appears to be a useful alternative to plasma monitoring, particularly for those patients in whom plasma sampling is unsuitable or impossible.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Workman, P., Wiltshire, C., Plowman, P. et al. Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer 38, 709–718 (1978). https://doi.org/10.1038/bjc.1978.277
Issue Date:
DOI: https://doi.org/10.1038/bjc.1978.277
This article is cited by
-
Saliva as a sampling source for the detection of leukemic fusion transcripts
Journal of Translational Medicine (2014)
-
Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors
Cancer Chemotherapy and Pharmacology (1987)
-
Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice
Cancer Chemotherapy and Pharmacology (1980)
